Claforan - General Information
Claforan is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Claforan sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
Pharmacology of Claforan
Claforan is a third generation intravenous cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. Claforan works by inhibiting bacterial cell wall biosynthesis. A positive feature of cefotaxime is that it display a resistance to penicillinases and is useful to treat infections that are resistant to penicillin derivatives.
Claforan for patients
Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
Drug/Laboratory Test Interactions
Cephalosporins, including cefotaxime sodium, are known to occasionally induce a positive direct Coombs' test.
CLAFORAN is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium or the cephalosporin group of antibiotics.
Additional information about Claforan
Claforan Indication: Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
Mechanism Of Action: The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Claforan shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III.
Drug Interactions: Amikacin Increased risk of nephrotoxicity
Gentamicin Increased risk of nephrotoxicity
Kanamycin Increased risk of nephrotoxicity
Neomycin Increased risk of nephrotoxicity
Netilmicin Increased risk of nephrotoxicity
Probenecid Probenecid increases the antibiotic's level
Streptomycin Increased risk of nephrotoxicity
Tobramycin Increased risk of nephrotoxicity
Food Interactions: Not Available
Generic Name: Cefotaxime
Synonyms: Not Available
Drug Category: Anti-Bacterial Agents
Drug Type: Small Molecule; Approved
Absorption: Rapidly absorbed following intramuscular injection.
Toxicity (Overdose): Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Oral rat LD50 is over 20,000 mg/kg while intravenous rat LD50 is over 7,000 mg/kg.
Protein Binding: Not Available
Biotransformation: Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. The desacetyl metabolite has been shown to contribute to the bactericidal activity. Two other urinary metabolites (M2 and M3) account for about 20-25%. They lack bactericidal activity.
Half Life: Approximately 1 hour.
Dosage Forms of Claforan: Powder, for solution Intravenous
Chemical IUPAC Name: (6R,7R)-3-(acetyloxymethyl)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Chemical Formula: C16H17N5O7S2
Cefotaxime on Wikipedia: https://en.wikipedia.org/wiki/Cefotaxime
Organisms Affected: Enteric bacteria and other eubacteria